Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US (NCT04743908), a randomized na study. The primary outcome is Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested)..

2. Clinical Question

3. Trial Design

This was a randomized, parallel-group study with no masking. The registry lists an enrollment of 1328 participants and a completed study. The two groups were Social Network Strategy (SNS Condition) and Social Network Strategy + Messaging. The registry identifies one intervention as Social Network Strategy + COVID-19 messaging; the arm descriptions name the two conditions but do not fully document their operational differences.

The project aimed to engage vulnerable communities at rural and urban sites across Texas, Louisiana, Arkansas, Indiana, and Illinois. The populations of interest were criminal justice-involved people who were not incarcerated and low-income Latinx community members. The registry notes that these groups can overlap, but does not report the enrolled participants’ distribution by population, location, or overlap.

The brief project description mentions a target of n=2400 for recruiting, enrolling, and testing community members, while the registry’s enrollment figure is 1328. The record does not explain the relationship between the project target and the listed enrollment. Allocation concealment, the randomization sequence, the ratio of allocation, and any stratification or blocking procedures are not reported in the registry record.

The study started on 2021-04-29 and had primary completion on 2022-12-31. The phase is listed as NA, and the sponsor is the University of Chicago. The registry record does not report whether participants or staff were blinded to group assignment; it does list masking as none. These design details set the context for interpreting the posted outcome and safety information, but they do not establish the size or precision of any treatment contrast.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested)., measured over 21 days from initial study visit for each participant.

The primary endpoint was the total number of network members referred for COVID testing who were tested through the social network strategy. It was measured at the participant level, with the timeframe defined as 21 days from each participant’s initial study visit. In practical terms, the outcome counts tested network members associated with a participant, rather than describing an individual participant’s own test result.

A count of network members tested is relevant to an intervention that uses social connections to extend testing beyond the person initially engaged. It can describe the reach of referrals during the stated follow-up period. It does not, by itself, indicate whether tests were positive, whether people received vaccination, or whether the approach changed health outcomes. Those conclusions would require distinct outcomes and appropriate analyses.

The registry lists the endpoint as a participant count and provides a description of how it was measured. However, it does not report group-specific outcome values or a statistical comparison for this endpoint. The registry record also notes that the primary outcome has several categories or time points and is not reduced to one comparison. Consequently, the primary question cannot be answered from the posted result information alone.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The statistical information in a registry record has several layers: the design, the outcome definition, the analysis plan, and the results. For this trial, randomization and a parallel-group structure are recorded, and the primary endpoint is defined as a count of network members tested through the social network strategy during a 21-day period. A statistical comparison of that endpoint is not reported in the registry record. The concepts below explain how such information is generally interpreted; they do not describe methods known to have been used in this trial.

What does randomization contribute?

In general, random assignment is intended to make the groups comparable at the start of a study, on average, with respect to measured and unmeasured characteristics. It does not ensure that every characteristic will be balanced in a particular trial. Assessing the assignment process and the analysis requires details such as how the sequence was generated, whether assignment was concealed, and which participants were included in each analysis. Those details are not reported in the registry record. Randomization alone cannot tell readers what the endpoint result was or how precisely it was estimated.

How should a count endpoint be analyzed?

A count records how many events or items occur for each observational unit. Here, the unit is the participant and the counted items are network members tested through the strategy. General count-data methods can compare group averages or model expected counts, but the choice depends on the research question, the distribution of the data, and design features such as differing observation time or clustering. The registry specifies a 21-day timeframe for each participant, but does not report a model, an estimated group contrast, or the underlying count distribution.

Some count outcomes vary more widely than a simple statistical model expects. This is called over-dispersion. When it is present, an analysis that assumes less variability than the data contain can produce uncertainty estimates that are too narrow. Other possible features of count data include many zero values or unusually large counts. General methods can account for such features, but the registry record does not report whether they were assessed or which method, if any, was used. It would be inappropriate to infer an analysis model from the endpoint’s count format alone.

What does an uncertainty interval convey?

In general, a confidence interval expresses the precision of an estimated contrast under the assumptions of the chosen analysis. A narrow interval indicates greater statistical precision than a wide interval, while the interval’s position relative to a value of no difference can help readers assess compatibility with different effects. It does not describe every source of uncertainty, such as bias from missing data or limitations in outcome measurement. No confidence interval for the primary comparison is reported in the registry record.

A p-value, when reported, is a measure tied to a specified statistical model and null hypothesis. It is not the probability that the null hypothesis is true, and it does not measure the size or practical importance of an effect. The registry record does not report a primary-outcome p-value or the test used. Therefore, neither a statistical-significance statement nor an effect-size interpretation can be reconstructed from the design details alone.

What can planning calculations tell readers?

Planning calculations concern the amount of information a study would need under specified assumptions; they are not observed trial results. The stated planning illustration uses a two-sided significance level of 0.05, equal allocation between the two arms, a normal approximation, and an effect defined as a stated fraction of the observed effect. The record describes participant counts per arm for non-time-to-event outcomes and total event counts for time-to-event outcomes. It does not report the resulting sample-size values in the information available for this analysis, nor does it report the trial’s own sample-size justification. Such planning figures should not be treated as observed power or as evidence that an outcome effect was found.

The listed enrollment of 1328 is a study-level count, not an outcome result. The project description also mentions a goal of n=2400, but the record does not explain how that goal relates to the enrollment figure. A sample-size target, even when documented, cannot substitute for group-specific outcome data, an effect estimate, or a measure of precision.

10. Multiplicity, Missing Data and Analysis Populations

Multiplicity arises when a study evaluates multiple outcomes, comparisons, time points, or analysis choices. In general, testing many hypotheses can increase the chance of at least one apparently notable result by chance. A statistical plan may specify a primary hypothesis, an order of testing, or an adjustment procedure. Such choices need to be reported to understand how results should be read.

The registry lists two outcome measures and states that the primary outcome has several categories or time points and is not reduced to one comparison. It reports zero analyses. The hierarchy among outcomes, any multiplicity adjustment, and any interim analyses are not reported in the registry record. No correction or testing strategy should be assumed.

Missing-data handling is also not reported. The record does not state how many participants contributed primary-outcome data, whether follow-up was complete, why any observations might be missing, or whether an imputation or sensitivity analysis was used. It also does not identify an analysis population, such as all randomized participants or participants with observed outcome data. These omissions prevent assessment of how missingness or analysis-set selection may affect a result.

These gaps matter because multiplicity and missing data concern the reliability and interpretation of an estimate, not just its presentation. Without a documented analysis plan and outcome results, the registry entry does not establish which comparison was primary in practice or how uncertainty from these issues was handled.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Serious events with the highest arm-level rate: hospitalization (0.2%).

The registry reports safety counts separately for the two groups. In Social Network Strategy (SNS Condition), 1 serious event is listed among 661 at risk, 0 other events among 661 at risk, and 1 death. In Social Network Strategy + Messaging, 0 serious events are listed among 667 at risk, 0 other events among 667 at risk, and 2 deaths. These are descriptive counts; they do not, by themselves, establish whether an event was caused by an intervention.

Hospitalization is listed at 0.2% among the serious-event terms. The record does not provide further detail about the cases represented by this term or its group distribution in the information. It also does not explain whether deaths overlap with serious events, how events were collected, or what follow-up period applies to these safety counts. No inferential comparison of safety outcomes is reported in the registry record.

Safety figures should therefore be read as the recorded counts and at-risk totals, not as proof of equivalence between groups or proof of a causal safety effect. The small number of listed events also means that the counts alone offer limited information about the range of plausible differences. This is a general caution about interpreting sparse event data, not a conclusion about the cause of any event in this study.

12. What the Result Does, and Does Not, Mean

The trial addresses a public-health implementation question: whether a social network testing strategy paired with community-developed COVID-19 messaging could differ from the social network strategy alone in the number of referred network members tested. The registry identifies the target communities, the two group labels, the randomized design, and the 21-day participant-level count outcome. These details clarify what the study set out to compare.

The posted information does not report the primary outcome comparison. There is no group-specific count, estimated contrast, confidence interval, or p-value in the registry record. Accordingly, the available information cannot establish whether the combined strategy was associated with more or fewer network members tested, or how precisely any difference was estimated. This is not the same as finding no difference; it is an absence of a reported comparative result.

The endpoint concerns testing reach through network referrals. It is not a measure of test positivity, vaccination uptake, infection prevention, or health outcomes. The project description mentions testing and vaccination, but the primary endpoint named in the registry is the count of network members tested. Conclusions about outcomes beyond that measure would require other reported results.

The safety counts offer a limited descriptive account of recorded events and deaths, but they do not determine causation or establish a comparative safety conclusion. The registry record also lacks details about missing outcomes, the analysis population, and the statistical plan. Thus, the strongest interpretation is bounded: the study was randomized and completed, with the stated endpoint and recorded safety counts, while its primary comparative result and the information needed to judge its precision are not reported in the registry record.

13. Why This Trial Matters Statistically

This study is statistically relevant because its endpoint reflects how an intervention may operate through social connections. A participant-level count of network members tested represents reach beyond the participant who entered the study. Such an endpoint differs from a simple individual-level clinical outcome: interpretation depends on clearly defining whose tests count, the observation period, and how network referrals are attributed. The registry defines the count and a 21-day timeframe, but does not report comparative results.

The population focus also makes transparent reporting important. The project sought to engage criminal justice-involved people who were not incarcerated and low-income Latinx community members across rural and urban sites in several Central US states. The registry describes potential overlap between the populations, but does not report how participants were distributed across groups or sites. Without that information, readers cannot assess whether effects varied across these communities or whether one group contributed more observations.

More broadly, the record illustrates why a completed randomized study is not automatically interpretable as an efficacy or effectiveness result. Randomization describes assignment; it does not replace an outcome estimate, an uncertainty interval, or an account of missing data and analysis populations. For count outcomes, readers also need enough information to understand variability and the chosen statistical method. Those elements are not reported for the primary comparison.

The result is a clear distinction between knowing the study question and knowing its answer. The record supports understanding the trial’s broad design and outcome definition, while leaving the estimated effect and its precision unavailable. That distinction matters when assessing evidence, comparing studies, and deciding what questions a registry entry can answer.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting this trial is that the registry record does not report a comparative result for the primary endpoint. Group-specific counts, an effect estimate, a measure of uncertainty, and a p-value are absent. The registry also indicates that the primary outcome has several categories or time points and is not reduced to one comparison, leaving the intended primary contrast unclear.

Descriptions of the two intervention conditions are incomplete. The project summary describes combining an evidence-based social network testing strategy with community-developed public-health messages, but the detailed arm descriptions are truncated. The available record therefore does not fully establish what differed between the strategies in implementation or message delivery.

The registry lists enrollment of 1328, while the project description mentions a goal of n=2400. The record does not explain the difference between these figures. It also does not report the number of participants with usable primary-outcome data, the distribution of participants among the target populations and sites, or the treatment of missing observations. The randomization procedure, allocation ratio, and analysis population are not reported.

Additional limits include the absence of a reported analysis plan, model specification, multiplicity procedure, and interim-analysis information. The safety counts are descriptive and are not accompanied by enough detail to establish event attribution or a comparative safety analysis. These are limitations of what the registry record makes available for interpretation; they should not be mistaken for proof that particular procedures were or were not used in the study.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US — NCT04743908.
• Registry record last updated 2024-10-10; status last verified 2024-04.
• Results first posted 2024-10-10.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT04743908 is a completed, randomized, parallel-group study sponsored by the University of Chicago. It lists no masking and a phase of NA. The study started on 2021-04-29, had primary completion on 2022-12-31, and lists enrollment of 1328.

The groups were Social Network Strategy (SNS Condition) and Social Network Strategy + Messaging. The primary endpoint counted network members tested through the social network strategy at the participant level over 21 days from each participant’s initial study visit. The study focused on criminal justice-involved people who were not incarcerated and low-income Latinx community members in rural and urban Central US settings.

A primary comparative result and analysis details are not reported in the registry record. Safety information lists serious events, other events, and deaths by group, with hospitalization recorded at 0.2% among serious-event terms. These entries describe the posted record but do not establish treatment effects or event causation.